COURTNEY ODOM: Open Payments
NPI 1962095612 · MC COLL, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$340 in 19 payments from 8 companies in 2025. Trend: 2023 $489 · 2024 $311 · 2025 $340
Food & beverage: $340
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 8 | $146 |
| Vanda Pharmaceuticals Inc. | 2 | $40 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $36 |
| ABBVIE INC. | 2 | $35 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $29 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Amgen Inc. | 1 | $16 |
| AstraZeneca Pharmaceuticals LP | 1 | $15 |
Products named: Ozempic, FANAPT, CAPLYTA, Kerendia, Wegovy, GVOKE HYPOPEN, VRAYLAR, Rybelsus.
Industry payments across SC — which companies pay providers there.
